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CC BY-NC-ND license.Obesity is a global epidemic that increases the risk of
type 2 diabetes, cardiovascular disease, and other medical
conditions that lead to premature mortality and more years
lived with disability [1]. However, obesity is a heteroge-
neous disorder in which the fat distribution confers dif-
ferential cardiometabolic risks [2]. In most studies,
anthropometric measures of abdominal fat are superior
measures of incident coronary heart disease events than is
total adiposity estimated by the body mass index (BMI) is
[3e10]. Associations between coronary heart disease risk
factors and events are stronger when visceral adipose tissue
(VAT) is measured directly by computerized tomography
or magnetic resonance imaging than by indirect measures
of central adiposity such as the waist circumference or the
waist-hip ratio or estimated by BMI [11e15]. High VAT
area has also been more strongly associated with charac-
teristics of vulnerable plaque than low VAT area or other
body compositional measures that included subcutaneous
adipose tissue area, waist circumference, and BMI [16].
Speciﬁcally, VAT was associated with noncalciﬁed plaque
burden as assessed by computerized tomography angiog-
raphy, as well as the presence of noncalciﬁed plaque with
positive remodeling and spotty calcium that represent
other characteristics of vulnerable plaque.
VAT is more metabolically active than subcutaneous
adipose tissue is, which results in increased ﬂux of
nonesteriﬁed fatty acids into the portal circulation. The
nonesteriﬁed fatty acids serve as substrates for triglyceride
production, which is incorporated into large very low-
density lipoprotein (VLDL) particles. Overproduction of
large VLDL particles and impaired catabolism in insulin-
resistant individuals results in transfer of core triglyceride
into LDL and high-density lipoprotein (HDL) particles.
Triglyceride-enriched LDL and HDL particles are substrates
for lipases that hydrolyze the triglyceride resulting in
smaller LDL and smaller HDL particles. Small LDL particles
are considered more atherogenic than large LDL particles
because of reduced clearance by LDL receptors and
increased oxidative susceptibility per particle.
High concentrations of large VLDL particles and
small LDL particles and low concentrations of large HDL
particles are associated with higher rates of coronary
artery disease in men [17] and predict future risk of
incident type 2 diabetes in previously healthy women
[18]. High LDL particle concentrations, particularly small
LDL particles, predict incident and recurrent cardiovas-
cular events in population-based cohorts [19,20] and
among coronary heart disease patients treated with lipid-GLOBAL HEART, VOL. 8, NO. 3, 2013
September 2013: 281-282lowering therapy [21]. Low HDL particle concentrations
are associated with increased cardiovascular events in
population-based studies [22,23] and clinical trials of
lipid-modifying therapies in multivariate models [21,24].
The reported associations from these prospective studies
and clinical trials that examine cardiometabolic risk and
lipoprotein subclasses were signiﬁcant in multivariate
models that included indirect measures of adiposity such
as BMI; however, none of the reports measured adiposity
directly.
In this issue of Global Heart, Hirooka et al. [25]
investigated the association between multiple measures of
adiposity (computerized tomography and anthropometric)
and nuclear magnetic resonanceemeasured lipoprotein
subclasses from a population-based sample of middle-aged
men of Japanese, Korean, and African American ancestry.
VAT was more strongly associated with high concentra-
tions of total LDL and VLDL particles and small LDL
particles and lower concentrations of large HDL particles
than subcutaneous adipose tissue, waist circumference,
and BMI in multivariate analysis that adjusted for age,
smoking, and alcohol consumption. The association of
VAT with these lipoprotein subclasses was similar regard-
less of ancestry. Unfortunately, the investigators did not
report whether these lipoprotein subclass associations were
different than those for plasma triglycerides and HDL
cholesterol, which are measures that have been correlated
with VAT in other studies [11,12] and incorporated into
the visceral adiposity index [2].
It is important to ask what clinically relevant infor-
mation has been learned from the current study and
what information is required from future studies. VAT is
more strongly associated with cardiometabolic risk fac-
tors in several studies including this report from Hirooka
et al. [25], and thus future reports that investigate the
cardiometabolic risk of adiposity will require VAT mea-
surements. Yet, it remains uncertain whether VAT and
certain lipoprotein abnormalities (high VLDL particle
concentration, high LDL particle concentration, or low
levels of large HDL particle concentration) considered in
isolation or in aggregate provide incremental information
concerning the risk of type 2 diabetes, atherosclerosis, or
cardiovascular events. Prospective studies will be
required to address the interactions of VAT and lipo-
protein subclasses and their functional properties on
incident type 2 diabetes and cardiovascular disease in
ethnically and racially diverse populations of men and
women [26].j.gheart.2013.08.002
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